Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6P179
UPID:
ERAP2_HUMAN
Alternative names:
Leukocyte-derived arginine aminopeptidase
Alternative UPACC:
Q6P179; Q7Z5K1; Q8TD32; Q8WVJ4; Q9HBX2
Background:
Endoplasmic reticulum aminopeptidase 2, also known as leukocyte-derived arginine aminopeptidase, plays a pivotal role in peptide trimming. This process is crucial for generating HLA class I-binding peptides, fitting longer precursor peptides to the required length for presentation on MHC class I molecules. It preferentially hydrolyzes basic residues Arg and Lys.
Therapeutic significance:
Understanding the role of Endoplasmic reticulum aminopeptidase 2 could open doors to potential therapeutic strategies. Its central role in peptide trimming, essential for immune response, highlights its potential as a target in designing novel immunotherapies.